Is Cardiff Oncology, Inc. (CRDF) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.6% / 30% | 45.4% / 30% | 0.1% / 30% | 523.44% / 5% | ✗ NOT HALAL |
| DJIM | 0.6% / 33% | 45.4% / 33% | 0.1% / 33% | 523.44% / 5% | ✗ NOT HALAL |
| MSCI | 1.3% / 33% | 94.2% / 33% | 0.3% / 33% | 523.44% / 5% | ✗ NOT HALAL |
| S&P | 0.6% / 33% | 45.4% / 33% | 0.1% / 33% | 523.44% / 5% | ✗ NOT HALAL |
| FTSE | 1.3% / 33% | 94.2% / 33% | 0.3% / 50% | 523.44% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -3221.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -71.5% | |
| Return on Assets (ROA) | -38.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$38M |
| Free Cash Flow | -$38M |
| Total Debt | $832,000 |
| Debt-to-Equity | 1.8 |
| Current Ratio | 3.7 |
| Total Assets | $62M |
Price & Trading
| Last Close | $1.67 |
| 50-Day MA | $1.91 |
| 200-Day MA | $2.46 |
| Avg Volume | 1.1M |
| Beta | 1.4 |
|
52-Week Range
$1.48
| |
About Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Cardiff Oncology, Inc. (CRDF) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Cardiff Oncology, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Cardiff Oncology, Inc.'s debt ratio?
Cardiff Oncology, Inc.'s debt ratio is 0.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.3%.
What are Cardiff Oncology, Inc.'s key financial metrics?
Cardiff Oncology, Inc. has a market capitalization of $106M, and revenue of $593,000. Return on equity stands at -71.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.